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Figure 5.  Illustration of NTC’s HyperGRO inducible fed-batch 
fermentation process using  an exponential feeding strategy and 
3042°C step  or slow ramp temperature profile. 
Results 
Plasmid based DNA vaccines are emerging as a promising alternative to traditional vaccines due to several 
advantages, including faster production of DNA plasmids using E. coli. However, further increases in transgene 
expression are needed to meet efficacy requirements for various non-viral gene therapy and DNA vaccination 
applications. While existing minicircle DNA technology has been shown to offer improved levels and durations of 
transgene expression by removal of the bacterial region from the plasmid, low manufacturing yields may be a 
barrier to widespread use of minicircle DNA for vaccination. 
 
Nature Technology Corporation’s (NTC’s) minimalized Nanoplasmid™ vectors utilize RNA-OUT (ROUT) antibiotic-free 
selection and replace the large 1000 bp pUC replication origin with a novel, 300 bp, R6K-derived mini-origin (Fig. 
1). Reduction of the spacer region linking the 5’ and 3’ ends of the transgene expression cassette to <500 bp 
remarkably increases plasmid-mediated transgene expression. Host strains expressing heat-inducible, high copy 
R6K replication (Rep) proteins have been developed for selection and propagation of Nanoplasmid. This is an 
additional Nanoplasmid safety factor since mini-origin vectors can only replicate within the engineered Rep 
protein-expressing E. coli host strain (Fig 2).  
 
With years of expertise in plasmid production, NTC and VGXI have successfully implemented NTC’s HyperGRO™ 
fed-batch fermentation process for traditional plasmid and Nanoplasmid production at yields >1 g/L. However, 
production of plasmids containing large antigen-coding inserts may have various challenges. Bacterial cell 
machinery may not be able to produce high cell growth during fermentation due to a large gene insert in the 
plasmid. A modified HyperGRO process was developed by NTC to overcome this cell growth inhibition. Plasmid 
pNano1, a 6689 bp Nanoplasmid with a gene insert of 5018 bp, was successfully produced by VGXI using NTC’s 
modified HyperGRO process, with high end cell density of OD600 90.1 and volumetric yield of 0.696 g/L. 
 
Further host strain engineering to repress plasmid copy number during biomass growth resulted in pNano1 
volumetric yield of 2.4 g/L after 42°C induction of high copy Nanoplasmid amplification (Fig. 8), which is near the 
highest published fermentation yield for any plasmid. 
Fig. 2: Antibiotic-Free (AF) RNA-OUT-R6K plasmid 
selection and propagation. 
Fig. 8: pNano1 (NTC9385R Nanoplasmid) growth and yield 
profile of a modified HyperGRO fed-batch fermentation. Feeding 
for µ=0.26h-1; 3042°C slow ramp temperature induction. Host = 
NTC1050811. 0.02% arabinose  used in base medium to repress 
growth phase copy number. Final Nanoplasmid yield was 2.4 
g/L. 
Fig. 6: NTC8382-1 (pUC origin) growth and yield profile of a  
standard HyperGRO fed-batch fermentation using 3042°C step 
induction at ~55 OD600. Host = NTC4862. Final plasmid yield was 
2.2 g/L. 
Plasmids 
•pNano1 (6689 bp), Nanoplasmid consisting of 1671 bp NTC9385R backbone (Fig 1) with 5018 bp gene insert. 
•NTC8382-1 (8023 bp), pUC  origin, antibiotic-free (RNA-OUT) backbone with the same large gene insert. 
 
Plasmid and Nanoplasmid production host strains 
•E. coli NTC4862: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) expression cassette for 
antibiotic-free, sucrose selectable pUC plasmids. 
•E. coli NTC821601: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) and temperature 
inducible R6K Rep expression cassettes for antibiotic-free, sucrose selectable R6K miniorigin Nanoplasmids. 
•E. coli NTC1050811: DH5α-derived with chromosomally integrated RNA-IN-SacB (levansucrase) and temperature 
inducible R6K Rep expression cassettes for antibiotic-free, sucrose selectable R6K miniorigin Nanoplasmids, with an 
additional arabinose inducible Lambda cI repressor. 
 
 
NTC’s Nanoplasmid™ is a next generation technology for plasmid production with a promising future. Nanoplasmid™ 
advantages include: 
• Smaller spacer region  improved expression 
  improved immunogenicity 
• No antibiotic resistance marker. 
• Much higher production yields (>2 g/L) compared to minicircles. 
• Safety: engineered production host required; Nanoplasmids cannot replicate in endogenous or environmental bacteria. 
• Smaller overall size  higher potency 
                  increased shear resistance during delivery 
  more efficient downstream purification 
 
Fermentation process modifications overcame cell growth inhibition to allow high yield production of Nanoplasmids. 
Further host strain engineering resulted in Nanoplasmid production at similar or higher yields than pUC-origin plasmids (Fig. 
8 vs. Fig 6.). 
 
VGXI has effectively implemented  HyperGRO process modifications for Nanoplasmid production at the 10L scale. As a 
leader in the cGMP plasmid production, VGXI is committed to embolden innovation in the field to provide high quality 
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The VGXI product testing was performed by VGXI’s QC department. 
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Fig. 1:  NTC9385R Nanoplasmid™ vector. 
Assay   Units pNano1 
Concentration by A260 mg/mL 9.5 
Purity by A260/280 2.0 
Restriction CTS 
pH   7.3 
Host Cell Genomic  % 0.3 
Host Cell Protein (HCP) % ≤0.02 
Host Cell RNA  % ≤0.1 
Endotoxin EU/mg 0.5 
Forms by HPLC 
     Total Supercoil % 94 
     Total Circular % 99 
Table 1: Quality Control Testing of Purified Nanoplasmid  
Fig. 9: Gel analysis of lysis, Anion Exchange and Hydrophobic Interaction  






































































































































Materials and methods 
Figure 4. Schematic of the VGXI cell lysis process using AIRMIX4  technology and a 
scalable continuous capture method. (1) Cell Resuspension, (2) Alkaline Lysis Solution, 
(3) Low Residence High Shear Static Mixer, (4) Lysis Hold Coil, (5) Neutralization 
Precipitation Solution, (6) AIRMIX Column, (7) Crude Lysate, (8) Lysate Filtration, (9) 
Filtered Lysate Holding Tank, (10) USP Purified Water, (11) Static Inline Mixer, (12) AEX 
Membrane Load, (13) AEX Capture Membrane. 
Figure 3. Schematic of the VGXI 
manufacturing process from receipt of a 
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Plasmid (mg/L) 
Fig. 7: pNano1 (NTC9385R Nanoplasmid) growth and yield 
profile of a modified HyperGRO fed-batch fermentation. Feeding 
for µ=0.26h-1; 3042°C slow ramp temperature induction. Host = 
NTC821601. Final Nanoplasmid yield was 0.57 g/L. 
Fermentation 
14L fermentors (New Brunswick Scientific) were employed at NTC and VGXI to perform 10L fermentations. A semi 
defined formulation was used for base and feed media, and 3042°C temperature profiles were used to induce 
high copy plasmid amplification. Exponential feeding is used to control the specific growth rate (Fig. 5) during the 
early fed-batch phase for biomass accumulation. With pUC-type plasmids,  the specific growth rate is controlled at 
µ = 0.12 h-1. However, with Nanoplasmids containing a large insert, this low growth rate results in early growth 
inhibition due to excessive plasmid content. Controlling the specific growth rate at µ = 0.26 h-1 (near 30°C µmax) 
keeps the Nanoplasmid copy number low to allow high biomass accumulation, before the temperature induced 
high copy Nanoplasmid amplification. 
 
Purification 
The VGXI Patented Airmix® Lysis Process is one of the most critical steps in the purification process. During this 
step, the cell paste of pNano1 was suspended in the resuspension solution and mixed with the lysis solution using 
a static mixer. The introduction of air bubbles at the precipitation step aids in low shear mixing and results in more 
efficient removal of impurities like genomic DNA and host cell proteins. The lysis step was optimized for the 
plasmids with the NTC backbone by increasing the incubation time of the crude lysate before filtering. The plasmid 
concentration increases during this incubation, perhaps by diffusion of plasmid from the cell debris and better 
reannealing of the plasmid strands. As a result, higher step yield was observed at the end of lysis. 
•<500 bp bacterial region for  
improved expression & 
duration 
•Reduced size  more 
efficient transfection 
•No antibiotic resistance 
gene 
•Can only replicate in special 
Rep protein expressing host 
•Regulatory compliant 
The faster exponential feeding (µ = 0.26 h-1 
for Nanoplasmids was initiated at EFT 
(elapsed fermentation time) 15h accumulate 
biomass and keep the plasmid copy number 
low. At EFT 26h, a linear feeding rate was 
used with a slow ramp up of temperature 
from 30°C to 42°C to slowly induce plasmid 
production. At EFT 37.5h, a holding step at a 
lower temperature was performed for 30 
minutes to allow replication completion of 
new plasmid molecules to the supercoiled 
form, increasing yield and quality. 
 
A high volumetric plasmid yield of 0.696 g/L 
and specific plasmid yield of 2.77g/kg of cell 
paste, and final OD600 of 90.1 was 
achieved. At the end of the fermentation 
process, the cells were harvested using a 
semi-continuous centrifugation process. 
 
pNano1 was purified from the cell paste as 
described (Figs. 3 & 4), achieving impurity 
levels (HCP, RNA, gDNA, endotoxin) much 
lower than FDA approved levels for clinical 
use (Table 1). 
 
 
NTC Process Development 
VGXI Production and Purification of pNano1 
in E. coli NTC821601 




















































































































































































      6689bp 
 6689 bp 
